Researchers from Bristol Myers Squibb Co. disclosed the structure and presented preclinical data for the dual inhibitor of diacylglycerol kinases (DGK) α and ζ, BMS-986408. Optimization of a DGK-α-selective hit led to the synthesis of dual DGK-α and -ζ inhibitors.
Recent Beigene Ltd. patents describe condensed heterocyclic compounds acting as diacylglycerol kinase α (DGK-α) and/or DGK-ζ (DGK-ζ) inhibitors and reported to be useful for the treatment of cancer.
Incyte Corp. has synthesized diacylglycerol kinase α (DGK-α) and/or diacylglycerol kinase ζ (DGK-ζ) inhibitors reported to be useful for the treatment of cancer.
Gossamer Bio Inc. has divulged diacylglycerol kinase α (DGK-α) and/or diacylglycerol kinase ζ (DGK-ζ) inhibitors reported to be useful for the treatment of cancer and viral infections.
Incyte Corp. has patented heteroaryl fluoroalkenes acting as diacylglycerol kinase α (DGK-α) and/or diacylglycerol kinase ζ (DGK-ζ) inhibitors and thus reported to be useful for the treatment of cancer.
Ono Pharmaceutical Co Ltd. has identified diacylglycerol kinase α (DGK-α, DGKA) and/or diacylglycerol kinase ζ (DGK-ζ, DGKZ) inhibitors reported to be useful for the treatment of cancer.
Bristol Myers Squibb Co. has identified tetrazole derivatives acting as diacylglycerol kinase α (DGK-α; DGKA) and/or diacylglycerol kinase ζ (DGK-ζ; DGKZ) inhibitors reported to be useful for the treatment of cancer and viral infections.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described bicyclic tetrahydrothiazepine derivatives acting as diacylglycerol kinase α (DGK-α, DGKA) and/or diacylglycerol kinase ζ (DGK-ζ, DGKZ) inhibitors reported to be useful for the treatment of cancer.
